Menu
← Oncology Approval Tracker
FDA DECISION ·
Hernexeos
zongertinib · Boehringer Ingelheim
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic nonsquamous NSCLC with an activating HER2 (ERBB2) tyrosine kinase domain mutation identified by an FDA-authorized test. Prior systemic therapy is no longer required.
LAMPGEN ANALYSIS
Why it matters
This expands HER2-targeted treatment to include patients without prior systemic therapy for advanced disease. Beamion LUNG-1 evaluated the untreated cohort used for this decision.
What research teams should watch
Screen for the specific HER2 kinase-domain alteration and capture treatment timing. Track the confirmatory study before drawing comparative conclusions.
PRIMARY RECORDS